Basic Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2018; 24(48): 5491-5504
Published online Dec 28, 2018. doi: 10.3748/wjg.v24.i48.5491
Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody
Winn Aung, Atsushi B Tsuji, Aya Sugyo, Hiroki Takashima, Masahiro Yasunaga, Yasuhiro Matsumura, Tatsuya Higashi
Winn Aung, Atsushi B Tsuji, Aya Sugyo, Tatsuya Higashi, Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Chiba 263-8555, Japan
Hiroki Takashima, Masahiro Yasunaga, Yasuhiro Matsumura, Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba 277-8577, Japan
Author contributions: Aung W designed the research, performed the majority of experiments and analyzed the data; Takashima H, Yasunaga M and Matsumura Y provided the anti-TF antibody; Sugyo A participated in the animal experiments; Tsuji AB and Higashi T coordinated the research and helped for the manuscript preparation; Aung W wrote the manuscript; All authors revised and endorsed the final draft.
Supported by a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, No. 17K10460 (to Aung W).
Institutional review board statement: This study was reviewed and approved by the Institutional review board of National Institute of Radiological Sciences. No patients and patient derived samples were involved in this study.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of National Institute of Radiological Sciences. (Protocol No: 13-1022-6).
Conflict-of-interest statement: The authors declare no potential conflicts of interest relevant to this article.
Data sharing statement: All relevant data were presented in the manuscript. Further information is available from the corresponding author at winn.aung@qst.go.jp.
ARRIVE guidelines statement: ARRIVE Guidelines have been adopted and authors uploaded the PDF version of the completed ARRIVE checklist to the system.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Winn Aung, MBBS, PhD, Senior Researcher, Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. winn.aung@qst.go.jp
Telephone: +81-43-3823706 Fax: +81-43-2060818
Received: October 2, 2018
Peer-review started: October 2, 2018
First decision: November 1, 2018
Revised: November 7, 2018
Accepted: November 16, 2018
Article in press: November 16, 2018
Published online: December 28, 2018
Processing time: 86 Days and 22.1 Hours
Core Tip

Core tip: We examined whether anti-tissue factor (TF) antibody 1849-indocyanine green (ICG) conjugate (1849-ICG) induced the photoimmunotherapeutic effect in a pancreatic cancer xenograft. There was no report about employing 1849-ICG conjugate which selectively binds the target antigen TF for near-infrared photoimmunotherapy (NIR-PIT) of tumor, though some studies have suggested the usefulness of anti-TF 1849 in cancer imaging and therapy. Our study proposes for the first time that 1849-ICG conjugate is a desirable candidate for new treatment modality NIR-PIT of pancreatic cancer after evaluating its cytotoxic and antitumor effects via in vitro and in vivo studies in mouse model of pancreatic cancer.